Dr. Elena Rostova
MD, FAAP — Chief of Neonatology & Medical Director of Level III/IV NICU
Neonatal-Perinatal Medicine & Critical Care
Biography & Clinical Philosophy
Dr. Elena Rostova brings profound dedication to the care of critically ill premature newborns. Having completed her fellowship at Vanderbilt University, Dr. Rostova has pioneered developmental neuro-protective ventilation strategies and published extensively on the mitigation of bronchopulmonary dysplasia.
Education & Medical Training
Degrees & Medical Education
- MD — Columbia University Vagelos College of Physicians and Surgeons
- BS in Molecular Biology — UNC Chapel Hill
Residencies & Fellowships
- Pediatric Residency — NewYork-Presbyterian Morgan Stanley Children’s Hospital
- Neonatal-Perinatal Fellowship — Monroe Carell Jr. Children’s Hospital at Vanderbilt
Clinical Research & Academic Inquiries
Non-invasive surfactant administration (LISA) and neonatal respiratory support.
Sacred Heart Journal Publications (1)
Browse In RepositoryLess Invasive Surfactant Administration (LISA) in Extremely Preterm Neonates (24–28 Weeks Gestation): Neurodevelopmental and Pulmonary Outcomes at 2 Years
Background: Non-invasive surfactant administration techniques seek to deliver exogenous surfactant while avoiding positive-pressure mechanical ventilation.\n\nMethods: In this prospective study of 188 extremely premature neonates born between 24+0 and 28+6 weeks gestation, patients receiving LISA via thin catheter during spontaneous breathing on CPAP were compared with standard InSurE technique.\n\nResults: The LISA cohort demonstrated a significantly lower rate of mechanical ventilation within the first 72 hours (28.7% vs 54.3%, p < 0.001) and a lower incidence of bronchopulmonary dysplasia (18.1% vs 31.9%, p = 0.028).\n\nConclusion: LISA is safe, feasible, and significantly reduces the duration of invasive mechanical ventilation in extremely preterm infants.
Get in Touch
For clinical inquiries, second opinions, and medical evaluations with Dr. Elena Rostova.